Introduction
Chromosomal translocations are often associated with specific hematological malignancies and have been shown to result in the fusion of genes or the transcriptional deregulation of affected genes. The rare but recurring t(10;11)(p13;q14) translocation, which was first characterized in the human monocytic cell line U937, results in the fusion of CALM on chromosome 11 band q14 to AF10 on chromosome 10 band p13 (Dreyling et al., 1996) . The resulting reciprocal fusion mRNAs encode fusion proteins of very unequal size ( Figure 1 ). The CALM/AF10 fusion encompasses nearly the complete open reading frames of both the CALM and AF10 genes, whereas the reciprocal AF10/CALM fusion essentially encodes for a truncated AF10 protein.
In patients, the occurrence of the CALM/AF10 rearrangement has been observed mainly in undifferentiated AML (FAB M0 or M1) or T-cell ALL and in malignant lymphoma and carries a rather poor prognosis (Dreyling et al., 1998; Kumon et al., 1999; Narita et al., 1999) . In T-ALL with T-cell receptor (TCR), g/d rearrangement the CALM/AF10 fusion is found in up to 30% of cases and constitutes the most frequent rearrangement in this leukemia subtype (Asnafi et al., 2003) . Recently, cases of more differentiated AML with a CALM/AF10 fusion have been reported (FAB M4, M5 and M7) (Carlson et al., 2000; Salmon-Nguyen et al., 2000; Jones et al., 2001; Abdou et al., 2002; Nakamura et al., 2003) . The translocation is observed in younger patients (Kobayashi et al., 1997; Dreyling et al., 1998; Silliman et al., 1998; Kumon et al., 1999) , and is also associated with mixed-lineage immunophenotype with coexpression of lymphoid (T-cell) and myeloid antigens (Kumon et al., 1999; Narita et al., 1999) .
In several patients, the t(10;11)(p13;q14) translocation has been described as the sole chromosomal abnormality Carlson et al., 2000; Abdou et al., 2002) , implying that the CALM/AF10 fusion plays a crucial role in leukemogenesis. It is very likely that the CALM/AF10 fusion transcript and not the reciprocal AF10/CALM fusion is critical in the leukemogenic process since only the CALM/AF10 and not the AF10/ CALM fusion transcript can be detected in all patients with a t(10;11)(p13;q14) (Dreyling et al., 1998; Narita et al., 1999; Bohlander et al., 2000; Carlson et al., 2000) . Indeed, we could recently show that the CALM/AF10 fusion gene causes an aggressive biphenotypic leukemia in a murine bone marrow transplantation model (Deshpande et al., 2003) .
The AF10 gene is one of the few MLL partner genes to be independently rearranged with a third gene in leukemia (Dreyling et al., 1996; Ayton and Cleary, 2001) . AF10 codes for a 1084 aa nuclear protein, which contains an N-terminal LAP/PHD (leukemia associated protein/plant homeodomain) zinc-finger motif, an extended LAP/PHD motif, a nuclear localization signal (NLS), an AT-hook motif, an octapeptide motif (OM), a leucine zipper (LZ) motif and a glutamic acid rich region (Q-rich region) Saha et al., 1995) .
CALM codes for a 652-aa ubiquitously expressed protein that shows extensive homologies to the neuronal-specific endocytic protein AP180 (Morris et al., 1993) . It functions as an endocytosis adaptor, which takes part in the initial stages of coated pit invagination together with clathrin, AP-2 and PtdIns(4,5)P 2 containing membranes. CALM interacts with the clathrin heavy chain through its C-terminal third and with phophoinositides through its AP180 N-terminal homology (ANTH) domain, promoting assembly of clathrin triskelia into clathrin cages in vitro (Ford et al., 2001 (Ford et al., , 2002 . Both overexpression or downregulation of CALM have been shown to inhibit receptor-mediated endocytosis and impair endosome trafficking in the trans Golgi network (Tebar et al., 1999; Huang et al., 2004) . The phenotype of AP180/CALM mutants of Drosophila (lap mutants) and Caenorhabditis elegans (unc11 mutants) suggested a role of these proteins in regulating the size of endocytic vesicles during the clathrin assembly process (Zhang et al., 1998; Nonet et al., 1999) . Point mutations in Picalm, the murine CALM homologue, result in disturbed hematopiesis, iron uptake metabolism and growth (Klebig et al., 2003) .
To further study the function of CALM and CALM/ AF10, we searched for CALM interacting proteins using a yeast two-hybrid (Y2 H) approach. A novel protein, which is strongly expressed in thymus, spleen and colon, was identified in this search. The corresponding gene was named CATS (CALM interacting protein expressed in thymus and spleen).
Results

CALM has a transcriptional activation domain
Initial experiments for the Y2 H screen showed that the full-length CALM protein fused to the DNA-binding domain of GAL4 (GAL4-DBD) activated the reporter genes HIS3 and LACZ. Using a series of deletion mutants of CALM, the transcriptional activation domain (TAD) of CALM was mapped to amino acids (aa) 408-572 of CALM (Figure 2 ).
CALM interacts with a novel protein in a Y2H screening
The N-terminal, non-transactivating 335 aa of CALM were used as a bait in a Y2H screen of HeLa cDNA prey library, which resulted in the isolation of seven clones encoding putative interacting proteins. Sequence analysis of these clones identified an 826 bp cDNA insert of an unknown gene. The sequence corresponded to the Cterminus of a protein (61 aa), which did not show homology to any other protein in the database. The newly identified gene was named CATS (CALM interactor expressed in thymus and spleen). In the completed human genome sequence, the computer generated name for this gene is FLJ10156. CATS is located on chromosome 17 band p13, 6.29 megabase pairs from the telomere of the short arm (chromosome 17 genomic contig NT_010718). There are four processed pseudogenes at other chromosomal locations (4p15, 4q24, 6q15 and 2q33). The genomic locus of CATS spans 7 kb and contains six exons with a noncoding first exon.
CATS codes for two isoforms
The splice donor and acceptor sites of CATS are canonical except for the third intron (between exons 3 and 4), which has a non-canonical splice donor site (GC instead of GT) ( Table 1) . Three alternatively spliced CATS transcripts were identified, which code for two protein isoforms of 238 and 248 aa in length (isoform 1 and 2, respectively) and a calculated molecular weight of about 26 kDa (Figure 3 ). Both isoforms share the first 228 residues, encoded by exons 2-4. The two proteins differ in their C-termini. The 10 last aa of isoform 1 are encoded by exon 5, which is absent in the transcript coding for isoform 2. The last 20 aa of isoform 2 are encoded by exon 6 (Figure 4) .
CATS is expressed predominantly in lymphoid organs
Multiple tissue Northern blot analysis revealed a 1.6 kb CATS transcript highly expressed in thymus, spleen and colon and to a lesser extent in the small intestines. Low levels of CATS transcript are also present in ovary and brain. In skeletal muscle and heart, transcripts of higher molecular weight are detected. These are most likely due to a longer 3 0 untranslated region ( Figure 5a ).
CATS is expressed in cells from leukemia patients carrying the CALM/AF10 rearrangement RT-PCR was performed in order to determine CATS expression in leukemic cells carrying the t(10;11). For this analysis, the U937 cell line as well as cells from four leukemia patients were used. Three different CATS transcripts were amplified in both patients carrying the CALM/AF10 fusion (patients 1: T-ALL and patient 2: AML). Similar expression levels of CATS were observed in one of the T-ALL patients negative for the CALM/ AF10 fusion (patient 3). High CATS expression was also observed in the CALM/AF10 fusion positive cell line U937 and in 293T. Sequence analysis revealed the three amplified fragments to be CATS splice variants 1, 2 and 3 (482, 441 and 775 bp) (Figure 5b ).
Mapping of CALM-CATS interaction in yeast
Since the CALM deletion mutants CALM(1-408), CALM(1-335), CALM(1-294) but not CALM(1-221) interacted equally with both CATS isoforms, the CATS interaction domain of CALM was mapped to aa 221-294 of CALM for both CATS isoforms. Interestingly, the C-termini of CATS isoform 1 and 2 (the last 51 and 61 aa, respectively) did not interact with CALM(1-294), but showed interaction with CALM(1-235) and CALM(1-408), suggesting that the C-termini of CATS require aa 294-335 of CALM for interaction ( Figure 6a and b). We also examined whether CATS interacts with itself by re-transforming CATS prey clones (full-length of both isoforms plus deletion mutants) with the fulllength of isoform 1 fused to the GAL4-DBD into yeast cells. Yeast clones containing both bait and prey plasmids did not activate the reporter genes, indicating that CATS does not interact with itself.
CALM interacts with CATS in vitro
To confirm that CALM and CATS interact physically, a glutathione S-transferase (GST) pulldown assay was performed. The fusion protein GST-CATSv2CT (aa 188-248, C-terminal domain of isoform 2) clearly retained the radiolabeled CALM protein ( Figure 7a , lane 2), while GST alone did not retain radioactive label ( Figure 7a , lane 1).
CALM interacts with both CATS isoforms in vivo
To establish whether endogenous CALM interacts with CATS, fluorescently tagged CATS fusion proteins (isoform 1 and 2) were expressed in 293T cells and precipitated with an antibody against the green fluorescent protein (GFP). The GFP antibody detected the immunoprecipitated GFP-CATS fusion proteins as shown in Figure 7b , upper lanes 2 and 4 (isoform 1 and 2, respectively). The membrane was stripped and reprobed with goat polyclonal anti-CALM antibodies, which identified two bands of the expected size for endogenous CALM (66 and 72 kDa) in the lanes with 
CATS is a nuclear and nucleolar protein
To determine the intracellular localization of CATS, yellow and cyan fluorescent protein (YFP and CFP) tagged CATS isoforms 1 and 2 were transiently expressed in NIH3T3 cells. These experiments showed an identical intracellular distribution for the two CATS isoforms (Figure 8g and h). Although no canonical NLS can be found in CATS, the CATS proteins were localized mainly in the nucleus and to a lesser extent in the cytoplasm and at the cell membrane (Figure 8b and e). Within the nucleus, CATS was enriched in one or several nodular structures. These structures were devoid of DAPI staining (Figure 8c ) suggesting that they were nucleoli. Coexpression of CFP-CATS with YFPnucleostemin, which was used as a nucleolar marker, revealed a colocalization of these proteins at the nucleolus (Figure 8j and k) .
CATS influences the subcellular localization of CALM and CALM/AF10
To further validate the CALM-CATS interaction and to study a possible influence that the expression of one protein might have on the subcellular localization of the 
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other protein YFP-CALM and CFP-CATS were coexpressed NIH3T3. These experiments showed that CATS (both isoforms) was able to influence the subcellular localization of CALM. If only YFP-CALM is expressed, it is localized predominantly in the cytoplasm and at the plasma membrane (Figure 8m ). However, in some cells in which CATS was coexpressed, CALM was observed both at the cytoplasm/membrane and in the nucleus at almost equal levels. The cytoplasmic portion of CATS colocalizes with CALM in the cytoplasm and at the membrane and the fraction of CALM that is shifted to the nucleus colocalizes with CATS in the nucleus (Figure 8o and p) . Interestingly, the effect of CATS on the subcellular localization of CALM was observed only in a minority of cotransfected cells. In order to address this differential effect of CATS on the subcellular localization of CALM, the transfected cells were examined at different time points after transfection. This showed that the effect of CATS on CALM localization is partially dependent on the time after transfection. No effect of CATS on CALM localization was observed up to 20 h after transfection but became noticable after 22, 28 and 48 h. However, there was no apparent difference in the proportion of cells in which CATS changed the subcellular localization of CALM at the time points 22, 28 or 48 h.
In order to test if CATS interacts also with the leukemic fusion protein CALM/AF10, CFP-CATS and YFP-CALM/AF10 were coexpressed. CALM/AF10 alone is predominantly localized in the cytoplasm with some YFP-CALM/AF10 also visible in the nucleus (Figure 8r ). In the presence of CFP-CATS, most of the YFP-CALM/AF10 protein is localized in the nucleus and even colocalizes with CATS at the nucleolus in some (Figure 8t and u). The nuclear localization effect of CATS seems to be stronger for CALM/AF10 than for CALM alone. However, like CALM, in some cells CALM/AF10 can also maintain its predominant cytoplasmic localization (data not shown).
Nuclear-cytoplasmic shuttling of CALM and CALM/AF10 proteins but not CATS The fact that CALM and CALM/AF10 accumulate in the nucleus of some CATS expressing cells together with the cytoplasmic and nuclear localization of CATS prompted us to investigate whether this is the result of a nuclear-cytoplasmic shuttling of the CATS protein.
Using leptomycin B (LMB), we inhibited the nuclear export of NIH3T3 cells that had been transiently transfected with YFP-CATS (both isoforms), YFP-CALM, and YFP-CALM/AF10. The relative distribution of nuclear and cytoplasmic CATS was not affected by LMB treatment, indicating that CATS does not shuttle between nucleus and cytoplasm (Figure 8a 0 , b 0 , d
0 , e 0 ). In contrast, both CALM and CALM/AF10 strongly accumulated in the nucleus. Interestingly, the leukemic fusion protein was nearly completely withdrawn from the cytoplasm and often revealed a speckled nuclear staining (Figure 8l 0 , m 0 , q 0 , r 0 ). These results show that both the CALM and CALM/AF10 proteins shuttle between nucleus and cytoplasm.
CATS isoform 1 acts as a transcriptional repressor in a GAL4-based transactivation assay Since CATS localizes mainly to the nucleus, we wanted to investigate a possible function of CATS as a transcriptional regulator. Expression of GAL4-DBD-CATS decreased the luciferase expression about 4.6-fold compared to GAL4-DBD alone (Figure 9 ).
Discussion
In order to further characterize CALM function and understand its contribution to CALM/AF10-mediated leukemogenesis, we used the N-terminal portion of CALM as a bait in a Y2H screen. A novel protein was identified as CALM interactor, which we named CATS (CALM interacting protein expressed in thymus and spleen). Northern blot analysis revealed that CATS is expressed strongly in thymus, spleen and colon.
Expression of fluorescent tagged CATS proteins showed that CATS localizes mainly to the nucleus where an accumulation of CATS is seen in the nucleoli. Some CATS protein is also observed in the cytoplasm and at the cell membrane. The CATS interaction region of CALM was mapped to aa 221-294 of CALM. As expected, the residues 1-221 of CALM does not interact with CATS. The Nterminal portion of CALM comprises the ANTH domain, which binds specifically lipids (PtdIns(4,5)P 2 ) in the membrane (Ford et al., 2001 (Ford et al., , 2002 De Camilli et al., 2002; Evans and Owen, 2002; Stahelin et al., 2003) . In contrast to the N-terminal domain which is composed of a-helices, the C-terminal two-thirds of CALM comprise poorly ordered protein domains containing multiple copies of various short protein interaction motifs (e.g. NPF) and behave like a flexible arm (Kalthoff et al., 2002) . This organization of CALM is thought to permit the establishment of complex networks of interactions during clathrin-coated pit assembly (Evans and Owen, 2002) . The fact that CATS interacts with this central domain of CALM suggests an involvement of CATS in this complex network of interactions in the endocytic machinery. However, the majority of the CATS protein localizes to the nucleus, implying also a nuclear function for this protein. In reporter gene assays, CATS functions as transcriptional repressor when it is fused to a DNA binding domain. Whether this observation is relevant for the physiological function of CATS needs to be explored further.
Interestingly, the CATS interaction domain of CALM is present in the CALM portion of both the CALM/ AF10 and the MLL/CALM fusion proteins. CATS not only colocalizes with CALM/AF10, but in some cells the subcellular localization of both CALM and CALM/ AF10 can be affected by the presence of CATS. CATS was able to increase the nuclear fraction of both CALM and CALM/AF10, and this effect seems to be stronger for the latter. Since we showed that not just CALM (as previously described by Vecchi et al., 2001 ) but also the CALM/AF10 fusion protein shuttle between nucleus and cytoplasm, it is tempting to speculate that the interaction between CATS and CALM or CALM/AF10 takes place in the nucleus, resulting in the accumulation of these proteins in the nucleus. These findings imply that in cells with high CATS expression, a greater portion of CALM and CALM/AF10 might be present in the nucleus. Considering the high expression of CATS in lymphoid tissues, the CATS-CALM interaction might play an important role in CALM/AF10 mediated leukemogenesis. These findings have to be interpreted with caution at the present time, however, because the change in CALM and CALM/AF10 localization was not observed in all cell coexpressing CATS and the two proteins.
The mechanisms by which the CALM/AF10 fusion protein causes leukemia are not known. One possibility would be a gain of function mechanism by which the CALM/AF10 fusion functions as a CALM protein with additional functions or as an AF10 protein with additional functions. Alternatively, the CALM/AF10 fusion protein might exerts its effect through a dominant negative mode of action, that is, disrupting normal AF10 and/or normal CALM function.
It is tempting to speculate that the CALM/AF10 fusion resides predominantly in the cytoplasm and thereby causes mislocalization of the wild-type AF10 protein from the nucleus into the cytoplasm through AF10 homo-dimerization. In the light of the CATS-CALM interaction, which is able to change the subcellular localization of CALM/AF10 to the nucleus, this scenario appears less likely. However, it could still be that through its interaction with CATS, the CALM/ AF10 fusion protein attains an abnormal subnuclear localization (e.g. a more nucleolar localization). Thus, it can be hypothesized that the CALM/AF10 fusion exerts its leukemogenic effect through a disruption of AF10 function. Since the Drososphila AF10 homologue alhambra has been shown to affect transcription regulation through Polycomb group-responsive elements (PREs), disruption of AF10 function could lead to transcriptional deregulation of polycomb and trithorax target genes (Perrin et al., 2003) . Indeed, deregulation of HOX genes has been observed in patients with CALM/ AF10 fusions (Delabesse et al., 2004; Krause et al., 2004) and HOX genes have also been identified as MLL/ AF10 targets (DiMartino et al., 2002) .
On the other hand, it is conceivable that the CALM/ AF10 fusion protein might disrupt the function of CALM through the mechanism of protein mislocalization. An altered CALM function might affect clathrin- CALM interactor CATS L Fröhlich Archangelo et al mediated endocytosis and protein trafficking in the trans-Golgi network. Indeed, Chao and co-workers have recently reported perturbed endocytosis when CALMcontaining fusion proteins were expressed in the cells (Chao et al., 2004) . Impairment of endocytosis could affect the downregulation of activated transmembrane receptors resulting in prolonged growth factor signaling leading to an increase in proliferative stimuli to the cell (Di Fiore and De Camilli, 2001 ).
As mentioned above, an alternative mode of action of the CALM/AF10 fusion protein would be a dominant gain of function mechanism. In this scenario CATS, which could be shown to have transcriptional properties when fused to a heterologous DNA binding motif, would be recruited to AF10 target genes through CALM, thereby deregulating AF10 target gene expression. This transcriptional deregulation could also be caused directly by the TAD of the CALM portion of the CALM/AF10 fusion protein (see Figure 2 ). There are reports that CALM is able to upregulate transcription when fused to a GAL4-DBD in a mammalian cell reporter gene assay (Vecchi et al., 2001) . However, we were unable to show a transcriptional activity of CALM in a similar system (data not shown). It should be noted that the CATS interaction domain of CALM and the CALM TAD map to distinct regions of the CALM protein. It remains to be tested which of these regions is critical for the transformation potential of the CALM/ AF10 fusion protein.
Since we could show that CATS is capable of recruiting the CALM/AF10 fusion protein to the nucleolus, there is a possibility that the AF10 portion of the fusion protein is disrupting nucleolar function. It was shown recently that many target genes of the protooncogene MYC are nucleolar proteins (Schlosser et al., 2003) and that the nucleolus plays a central role in cell proliferation and growth by controlling ribosome biosynthesis and p53 function (Tsai and McKay, 2002; and references therein) .
In summary, we propose that CATS is a critical modulator of normal CALM function in lymphoid cells and that CATS could be very important for understanding the leukemogenic potential of the CALM/ AF10 fusion protein.
Materials and methods
Plasmid construction
A full-length CALM cDNA clone was digested with appropriate restriction enzymes, and the resulting deletion mutants were cloned into yeast vectors (pAS2, pGBT9 or pGBKT7 from Clontech, Heidelberg, Germany) to be expressed as GAL4-DBD fusion proteins.
The complete CATS open reading frame and the CATS Ctermini were cloned into yeast vectors pGBKT7 and pGADT7 (Clontech, Heidelberg) to be expressed as GAL4-DBD and GAL4-AD fusion proteins. pGBKT7-CATSv1FL and pGADT7-CATSv1FL: Full-length of CATS isoform 1. pGADT7-CATSv1CT: C-terminus of CATS isoform 1 (aa 188-238). pGADT7-CATSv2FL: The CATS open reading frame of isoform 2.
GST fusion construct was generated by cloning the Cterminal portion of the CATS isoform 2 (aa 187-248, original prey clone insert) into the pGEX4T2 vector (Amersham Pharmacia Biotech, Freiburg, Germany).
Plasmids expressing GFP-, CFP-, YFP-CATS and YFP-CALM and -CALM/AF10 fusion proteins were constructed in the pEGFP-C1, pECFP-C1 or pEYFP-C1 vectors (Clontech, Heidelberg). For a detailed description of the constructs, contact the authors.
Yeast 2 hybrid screening and interaction domain mapping
The CG-1945 yeast strain was serially transformed with the bait plasmid pGBT9-CALM(1-335) and with an S3 HeLa cDNA library cloned in the pGADGH vector (Clontech, Heidelberg).
For protein interaction domain mapping, CALM deletion mutants fused to the GAL4-DBD and CATS isoforms or CATS C-termini fused to the GAL4-AD were cotransformed in the yeast strain AH109. Interaction between the proteins was assayed by yeast growth on s.d. plates lacking leucine, tryptophan, histidine and adenine in the presence of X-a-GAL.
Database searches
Human EST database was searched with the 826 bp sequence from the prey clone isolated from the Y2H screening. Three overlapping ESTs were identified (GenBank AA604379, BE888231, BE799806). Two IMAGE cDNA clones (IMAGp998G039611, IMAGp998D169579) corresponding to these EST sequences were obtained from the Resource Centre of the German Human Genome Project (RZPD; Berlin, Germany). Both IMAGE cDNA clones were completely sequenced. The human genomic sequence of CATS is contained in BAC RP11-636N17 (Accession Number AC055872). 
Expression analysis
Northern blots containing poly(A) þ RNA of different adult human tissues (MTN Blot I and II, Clontech, Heidelberg) were hybridized with a CATS cDNA fragment, according to manufacturer's instructions. The 731-bp 32 P-labeled probe corresponding to CATS open reading frame (exons 2-5, nt 74-805) was generated with the Megaprimet DNA labeling system (Amersham Biosciences, Freiburg, Germany).
For RT-PCR analysis, total RNA was isolated from approximately 4 Â 10 6 cells using the RNeasy s Mini Kit (Qiagen, Hilden, Germany) and QIAshreddert column. A total of 1 mg of DNAse I treated RNA was reverse transcribed with oligo dT primers and SuperScript II enzyme (Invitrogent Life Technologies, Karlsruhe, Germany). For amplification of CATS transcripts, PCR reactions were carried out in 20 ml with 1 ml of cDNA, 0.16 ml of PAN Script DNA Polymerase (PANt Biotech, Aidenbach, Germany) and 0.5 mM of CATS specific primers CATSE1F1(364) (5 0 -AAGAGTGCTTTGGGTGCC G-3 0 ) and CATSE5R1(828) (5 0 -CGGTCAGACAGGGCTTG TTTC-3 0 ). The annealing temperature used for the PCR reaction was 601C in a 30 cycle program.
GST pull-down assay Induction of GST-CATS(187-248) fusion protein expression in Escherichia coli strain BL21 (Stratagene, La Jolla, USA) was achieved with 0.1 mM IPTG. The GST-CATS(187-248) protein was purified with glutathione Sepharose 4B (Amersham Pharmacia, Freiburg). In vitro translation of full-length CALM was performed with rabbit reticulocyte lysate (Promega, Mannheim, Germany) and 35 S-labeled methionine. About 30 ml of immobilized GST-CATS(187-248) fusion protein and 25 ml of in vitro-translated CALM protein were incubated in 200 ml of bead-binding buffer (50 mM K-phosphate pH 7.5, 100 mM KCl, 10% glycerol (v/v), 0.1% Triton X-100) at 41C for 2 h. The beads were washed four times with bead-binding buffer without glycerol and Triton X-100, denatured and analyzed by SDS-PAGE and autoradiography.
Cell culture, transfections and epifluorescence microscopy NIH-3T3 (mouse fibroblast) and HEK293T (human embryonal kidney cells) cells were grown in DMEM supplemented with 10% heat inactivated FCS and antibiotics. Cells were transiently transfected with expression plasmids with Roti sFect reagent (ROTH, Karlsruhe, Germany).
Inhibition of nuclear export was performed by treating the cells 16 h after transfection with 100 nM LMB for 4 h.
For microscopy, cells were grown on 18 Â 18 mm coverslips. At 18-48 h after transfection, cells were washed in PBS, and fixed for 10 min in 3.7% formaldehyde/PBS. All photographs were taken on an automated Axiovert 200M microscope (Zeiss, Jena, Germany) equipped with single-band pass filter sets for visualization of CFP and YFP fluorescence. Images were recorded using the Openlab 3.08 software (Improvision, Coventry, UK) and pictures were processed with Adobe Photoshop s (Adobe Systems, Mountain View, CA, USA).
Protein extraction GFP-CATSv1 and YFP-CATSv2 fusion proteins were expressed in HEK293T cells. Cells were harvested, washed and lysed in RIPA buffer for 30 min on ice. Whole-cell extracts were cleared by centrifugation.
Immunoprecipitation
For each immunoprecipitation experiment, 400 mg total cellular lysate was used. Preclearing was performed by incubating the lysate with 30 ml Protein A-Agarose (Roche, Penzberg, Germany) and 2 mg normal rabbit IgG (Santa Cruz Biotechnology, Inc., Heidelburg, Germany) in 1 ml low stringency buffer (10 mM Tris-HCl pH 8, 50 mM NaCl and 0.5% Triton X-100) for 1 1 2 h. The resulting supernatant was then incubated at 41C for 5 h with 2 mg of either specific antibody or normal IgG, which had been previously incubated with 30 ml Protein A-Agarose for 1 1 2 h. Precipitates were washed three times with the buffer described above, resuspended in SDS sample buffer, incubated for 1 h at 561C and denatured for 5 min at 951C.
Immunoblotting analysis
Immunocomplexes and cellular lysates were electrophoresed on 8% SDS-PAGE and transfered onto nitrocellulose membrane (Hybondt ECLt, Amersham Pharmacia Biotech). Immunoblotting was carried out by using a mix of goat anti-CALM antibodies (G17, C18 and S19) (Santa Cruz Biotechnology, Inc.) or rabbit anti-GFP (Molecular Probes Europe BV, Leiden, The Netherlands).
Reporter gene assays 293T cells (3.2 Â 10 5 cell/35 mm plate) were cotransfected with 0.66 mg of the pM1-CATS construct, 0.33 mg of pGAL4 5 tk-LUC reporter plasmid (Netzer et al., 2001 ) and 6.6 ng of pRLnull co-reporter vector (Promega). After 48 h, cells were harvested and assayed for firefly and Renilla luciferase activities using a Dual-Luciferase Reporter Assay System (Promega). Measurements of Renilla luciferase activity were used for normalization.
